The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Lung Fibrosis after COVID-19: Treatment Prospects
Open accessAbstract
At the end of 2019, a highly contagious infection began its ominous conquest of the world. It was soon discovered that the disease was caused by a novel coronavirus designated as SARS-CoV-2, and the disease was thus abbreviated to COVID-19 (COVID). The global medical community has directed its efforts not only to find effective therapies against the deadly pathogen but also to combat the concomitant complications. Two of the most common respiratory manifestations of COVID are a significant reduction in the diffusing capacity of the lungs (DLCO) and the associated pulmonary interstitial damage. One year after moderate COVID, the incidence rate of impaired DLCO and persistent lung damage still exceeds 30%, and one-third of the patients have severe DLCO impairment and fibrotic lung damage. The persistent respiratory complications may cause substantial population morbidity, long-term disability, and even death due to the lung fibrosis progression. The incidence of COVID-induced pulmonary fibrosis caused by COVID can be estimated based on a 15-year observational study of lung pathology after SARS. Most SARS patients with fibrotic lung damage recovered within the first year and then remained healthy; however, in 20% of the cases, significant fibrosis progression was found in 5–10 years. Based on these data, the incidence rate of post-COVID lung fibrosis can be estimated at 2–6% after moderate illness. What is worse, there are reasons to believe that fibrosis may become one of the major long-term complications of COVID, even in asymptomatic individuals. Currently, despite the best efforts of the global medical community, there are no treatments for COVID-induced pulmonary fibrosis. In this review, we analyze the latest data from ongoing clinical trials aimed at treating post-COVID lung fibrosis and analyze the rationale for the current drug candidates. We discuss the use of antifibrotic therapy for idiopathic pulmonary fibrosis, the IN01 vaccine, glucocorticosteroids as well as the stromal vascular fraction for the treatment and rehabilitation of patients with COVID-associated pulmonary damage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy
George, P. M., Wells, A. U., & Jenkins, R. G. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30225-3 · Cited by 1,085
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005 · cited 1×
“Nintedanib binds to the intracellular ATP pockets of the corresponding receptors, which leads to the inhibition of pro-fibrotic signaling and the attenuation of the proliferation, migration, and differentiation of fibroblasts as well as extracellular matrix component secretion [51].”
BackgroundZhang, P., Li, J., Liu, H., Han, N., Ju, J., Kou, Y., Chen, L., Jiang, M., Pan, F., Zheng, Y., et al. (2020) · Bone Research · doi:10.1038/s41413-020-0084-5 · Cited by 440
Viral Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Wootton, S. C., Kim, D. S., Kondoh, Y., Chen, E., Lee, J. S., Song, J. W., Huh, J. W., Taniguchi, H., Chiu, C., Boushey, H., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201010-1752oc · Cited by 285
Current approaches to the management of idiopathic pulmonary fibrosis
Raghu, G., & Richeldi, L. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.05.017 · Cited by 90
Zhou, M., Yin, Z., Xu, J., Wang, S., Liao, T., Wang, K., Li, Y., Yang, F., Wang, Z., Yang, G., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab181 · Cited by 39
Cited by
Zeyada, M. S., Eraky, S. M., & El-Shishtawy, M. M. (2024) · Life Sciences · doi:10.1016/j.lfs.2023.122272 · Cited by 31
Metadata
- Authors
- Bazdyrev, E., Rusina, P., Panova, M., Novikov, F., Grishagin, I., & Nebolsin, V.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2021-08-17
- Volume
- 14
- Issue
- 8
- Pages
- 807
- ISSN
- 1424-8247 (ISSN-L)
- OpenAlex
- W3194743736
- Cited by
- 192
- References
- 6
- FWCI
- 24.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lung Fibrosis after COVID-19: Treatment Prospects. https://app.cochat.ai/papers/10.3390/ph14080807
- The paper
- Bazdyrev, E., Rusina, P., Panova, M., Novikov, F., Grishagin, I., & Nebolsin, V. (2021). Lung Fibrosis after COVID-19: Treatment Prospects. Pharmaceuticals. https://doi.org/10.3390/ph14080807
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.